Reagents, Reference Materials & Laboratory Chemicals
High-precision synthetic sediment standard for IRMS and TOC
Elemental Microanalysis, a global leader in elemental analysis supplies, has introduced the first in a new series of synthetic sediment standards designed for isotope ratio mass spectrometry (IRMS) and total organic carbon (TOC) analysis.
The new reference material, B2251, replicates the elemental composition of natural sediment using carefully selected mineral and chemical ingredients. This synthetic approach allows for precise tailoring to match specific matrix requirements, offering researchers a
closer fit for their analytical needs.
B2251 is a high-organic-content sediment standard certified for TOC, total carbon, nitrogen, and sulphur. Elemental’s R&D team plans to expand the range during 2025, developing additional synthetic standards to support studies on carbonate removal techniques and to simulate the IRMS behaviour of previously sourced natural soils and sediments.
Synthetic standards offer key advantages over natural equivalents: greater batch-to-batch consistency, fewer regulatory hurdles, and simplified global shipping thanks to the absence of export controls linked to irradiated natural soil.
Elemental Microanalysis also supplies a broad selection of synthetic soil standards certified for carbon, nitrogen, and sulphur content.
More information online:
ilmt.co/PL/O546 64703pr@reply-direct.com
Expanded antibody and reagent portfolio for bioanalysis
Bio-Rad Laboratories has broadened its collection of recombinant monoclonal anti-idiotypic antibodies, adding specificities for pertuzumab (Perjeta), guselkumab (Tremfya), canakinumab (Ilaris), belimumab (Benlysta), and the bispecific therapy emicizumab (Hemlibra). The company has also introduced a new Human IgM- FcSpyCatcher to its SpyCatcher reagent line.
The expanded anti-biotherapeutic antibody range supports the creation of robust, reliable bioanalytical assays for pharmacokinetic (PK) and anti-drug-antibody (ADA) studies. These tools help researchers monitor therapeutic drug levels for both innovator and biosimilar products, including the five newly added drug targets.
The Human IgM-FcSpyCatcher offers a novel way to rapidly generate pentameric and hexameric IgM formats at the protein level, enabling format switching without additional cloning. Fully compatible with Bio-Rad’s recombinant HuCAL antibodies, the reagent has been validated in ELISA, western blotting, and precipitation workflows.
All new antibodies and reagents are approved for in vitro research use. The anti-idiotypic antibodies are also cleared for use in commercial in vitro testing services, supporting preclinical and clinical drug development, biosimilar programs, and patient monitoring.
More information online:
ilmt.co/PL/bw2Z and
ilmt.co/PL/9Mvl 65524pr@reply-direct.com
Tailored Taq polymerases for qPCR and NGS-based protein assays
Biotium, a leading provider of fluorescent reagents for life science research, has expanded its trusted Cheetah™ Taq DNA Polymerase line with two powerful new formulations: Cheetah™ FLEX HotStart Taq DNA Polymerase and Cheetah™ PEA-PLEX HotStart Taq DNA Polymerase. These innovative products are engineered to meet the needs of today’s high-performance molecular workflows, from fast- cycling qPCR to proximity extension assays (PEA) and NGS-based high-throughput PEA for protein analysis.
Both formulations build on Biotium’s proprietary chemically modified, antibody-free hot-start technology, designed to reduce non-specific amplification without the limitations of antibody-based systems. The result is faster activation, improved stability, and broader compatibility with modern PCR applications.
Cheetah™ FLEX HotStart Taq is optimised for speed and versatility. It features a rapid 2-minute activation at 95°C - up to 10 times faster than AmpliTaq Gold® or HotStartTaq®—without the risk of animal DNA contamination. This antibody-free approach not only improves long-term storage stability but also ensures reproducibility across fast-cycling PCR and qPCR- based PEA workflows. Once heat activated, Cheetah™ FLEX performs with the same fidelity and enzymatic properties as native Taq polymerase, making it suitable for both routine and advanced protocols.
For researchers working with high-throughput PEA and NGS-based workflows, Cheetah™ PEA-PLEX HotStart Taq offers a purpose-built solution. Developed specifically for protein detection applications, it has been validated by third parties for use in NGS-based PEA systems and is also compatible with fast-cycling qPCR. Its formulation allows for seamless integration into demanding high-throughput assay environments.
Key benefits of both formulations include a unique chemical hot-start mechanism (no antibodies or activation lag), rapid 2-minute activation, enhanced contamination control due to the low-DNA enzyme preparation, and better stability than traditional chemically modified Taq enzymes. Cheetah™ PEA-PLEX is also available in ready-to-use kits or customisable bulk formats to suit the needs of commercial assay developers.
Both Cheetah™ FLEX and Cheetah™ PEA-PLEX are available now for purchase in standard and bulk quantities.
These latest additions join Biotium’s growing suite of advanced PCR tools, including the Forget-Me-Not™ qPCR Master Mixes and EvaGreen® Dye - formulated to deliver performance, reliability, and convenience for today’s molecular biologists. More information online:
ilmt.co/PL/A3YB and
ilmt.co/PL/vRpA
64846pr@reply-direct.com Validated antibodies support stem cell purity and consistency
AMSBIO has extended its antibody portfolio to support quality assurance in stem cell research and therapeutic development. The new antibodies offer high specificity and batch-to- batch consistency for techniques including flow cytometry, immunocytochemistry, Western blotting and ELISA.
Among the latest additions are monoclonal antibodies targeting key pluripotency markers - SSEA-3 (Gb5), SSEA- 4 (SialylGb5) and Lewis X (SSEA-1). These Stage-Specific Embryonic Antigens (SSEAs) are widely used to assess the undifferentiated state of human pluripotent stem cells and monitor early differentiation.
The antibodies are raised against glycan epitopes that are uniquely expressed on human stem cells, with minimal cross-reactivity to non-target glycans as confirmed by ELISA validation. This ensures accurate detection and reduces the risk of false positives in routine QC and research workflows.
Dr Philipp Boder, stem cell specialist at AMSBIO, said: “Whether for basic research or therapeutic development, antibody quality directly impacts reproducibility. Our rigorously validated antibodies help scientists confirm culture integrity and compare results across labs with confidence.” He added: “In regenerative medicine, this level of reliability is key to ensuring the safety and consistency of cell-based therapies.”
More information online:
ilmt.co/PL/NwOz 64869pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60
